Jeffrey M.
Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE
trial investigator, will join Avidity management to present data
from FORTITUDE™
Avidity to host Volume 9 of investor and
analyst event series via webcast June 12,
2024, at 8:00 a.m. ET
SAN
DIEGO, May 29, 2024 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced that
the company will be presenting one oral and one poster presentation
at the 31st Annual FSHD Society International Research Congress,
being held June 13-14, 2024, in
Denver, Colorado.
Jeffrey M. Statland, M.D.,
Professor of Neurology, University of Kansas
Medical Center, and FORTITUDE™ trial investigator, will
present preliminary data from the Phase 1/2 FORTITUDE™ clinical
trial of AOC 1020 in people living with facioscapulohumeral
muscular dystrophy (FSHD).
In addition, Avidity management will be joined by Dr. Statland
on June 12, 2024, at 8:00 a.m. ET for a live video webcast event to
discuss the AOC 1020 preliminary data from the FORTITUDE trial,
which will be available on the company's website.
ORAL PRESENTATION
June 14, 2024: 4:50 pm MDT
- Interim Results from FORTITUDE™, a Randomized Phase
1/2 Trial Evaluating AOC 1020 in Adults with FSHD
POSTER PRESENTATION
June 13, 2024: 7:00 –
8:30 pm MDT
- Increasing Diversity in Clinical Trial Participation: An
Exploration of Clinical Trial Site Engagement
The presentation and poster will be available on
the publications page of Avidity's website at
https://www.aviditybiosciences.com.
Video Webcast Information
The company is hosting
Volume 9 of its investor and analyst event series on June 12,
2024, beginning at 8:00 a.m. ET to discuss the
preliminary data from the FORTITUDE™ trial of AOC 1020 in
people living with FSHD. The virtual event will be available via a
live video webcast and can be accessed here or from the
"Events and Presentations" page in the "Investors" section of
Avidity's website. A replay of the webcast will be archived on
Avidity's website following the event.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve
people's lives by delivering a new class of RNA therapeutics -
Antibody Oligonucleotide Conjugates (AOCs™). Avidity is
revolutionizing the field of RNA with its proprietary AOCs, which
are designed to combine the specificity of monoclonal antibodies
with the precision of oligonucleotide therapies to address targets
and diseases previously unreachable with existing RNA therapies.
Utilizing its proprietary AOC platform, Avidity demonstrated the
first-ever successful targeted delivery of RNA into muscle and is
leading the field with clinical development programs for three rare
muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular
dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
Avidity is broadening the reach of AOCs with its advancing and
expanding pipeline including programs in cardiology and immunology
through internal discovery efforts and key partnerships. Avidity is
headquartered in San Diego, CA. For more information
about our AOC platform, clinical development pipeline and people,
please visit www.aviditybiosciences.com and engage with us
on LinkedIn and X.
Forward-Looking Statements
Avidity cautions readers
that statements contained in this press release regarding matters
that are not historical facts are forward-looking statements. These
statements are based on the company's current beliefs and
expectations. Such forward-looking statements include, but are not
limited to, statements regarding: the company's plans to discuss
preliminary data from its FORTITUDE™ study and to participate in
the 31st Annual FSHD Society International Research Congress. The
inclusion of forward-looking statements should not be regarded as a
representation by Avidity that any of these plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Avidity's
business and those beyond its control. Avidity cautions readers not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and the company undertakes no
obligation to update such statements to reflect events that occur
or circumstances that arise after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, which is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Investor Contact:
Geoffrey
Grande, CFA
(619) 837-5014
investors@aviditybio.com
Media Contact:
Navjot
Rai
(619) 837-5016
media@aviditybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-present-preliminary-data-from-phase-12-fortitude-trial-of-aoc-1020-in-people-living-with-facioscapulohumeral-muscular-dystrophy-at-31st-annual-fshd-society-international-research-congress-302158556.html
SOURCE Avidity Biosciences, Inc.